The Influence of H2 blocker on the Antiplatelet Effect of Clopidogrel

The Influence of H2 blocker on the Antiplatelet Effect of Clopidogrel - The Influence of H2 blocker on the Antiplatelet Effect of Clopidogrel

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003407

Enrollment

Registered

2010-03-30

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic heart disease

Interventions

patients taking H2 blocker famotidine, on low-dose (81-100 mg) aspirin and 75 mg of clopidogrel

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients on low-dose (81-100 mg) aspirin and 75 mg of clopidogrel

Exclusion criteria

Exclusion criteria: 1) contraindicative patients of aspirin and clopidogrel, 2) patients with warfarin, 3) patients with thrombolytic therapy within 2 weeks, and 4) patients taking ticlopidine, cilostazole or dipyridamole within 1 month 5)chronical renal failure(Cre>1.5)

Design outcomes

Primary

Measure	Time frame
Maximal Platelet Aggregation Rate after intake of H2 blocker	—

Countries

Japan

Contacts

Public ContactYoshihiro kato

Kyoto University Department of Cardiovascular Medicine

075-751-4255

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026